Osteoporosis, 2nd Edition

  • Published By:
  • ISBN-10: 0123982529
  • ISBN-13: 9780123982520
  • DDC: 616.716
  • Grade Level Range: College Freshman - College Senior
  • 2116 Pages | eBook
  • Original Copyright 2013 | Published/Released February 2014
  • This publication's content originally published in print form: 2013

  • Price:  Sign in for price



Now in its 4e, Osteoporosis is a classic reference on this disease, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume work is a must-have for academic and medical libraries, physicians, researchers, and any company involved in osteoporosis research and development. This newest edition covers everything from basic anatomy and physiology to diagnosis, management and treatment in which direct care costs for osteoporotic fractures in the United States reach up to $18 billion each year. Worldwide, 200 million women ages 60 to 80 suffer from osteoporosis and have a lifetime risk of fracture between 30% and 40%, continuing to make osteoporosis a critical challenge in medicine.

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
Preface to the Fourth Edition.
Editor's Note.
1: Introduction.
2: The Bone Organ System: Form and Function.
3: The Nature of Osteoporosis.
4: Reflections on Osteoporosis.
5: Reflections on Development of Concepts of Intercellular Communication in Bone.
6: Osteo-Odyssey: A Memoir.
7: Cellular, Molecular, and Developmental Biology of Bone.
8: Development of the Skeleton.
9: The Skeletal Stem Cell.
10: Osteoclast Biology.
11: Osteoblast Biology.
12: Osteocyte Biology.
13: The Regulatory Role of Matrix Proteins in Mineralization of Bone.
14: Skeletal Hormones and Regulatory Factors.
15: Parathyroid Hormone and Parathyroid Hormone-Related Protein.
16: Vitamin D: Biology, Actions, and Clinical Implications.
17: Regulation of Bone Cell Function by Estrogens.
18: Androgens and Skeletal Biology: Basic Mechanisms.
19: Phosphatonins.
20: Skeletal Growth Factors.
21: WNT Signaling in Skeletal Homeostasis and Diseases.
22: Skeletal Structure and Biomechanics.
23: The Mechanical Behavior of Bone.
24: Cellular and Molecular Mechanotransduction in Bone.
25: Adaptation of Skeletal Structure to Mechanical Loading.
26: Biomechanics of Hip and Vertebral Fractures.
27: Prevention of Osteoporosis by Physical Signals: Defining a Potential Role for Nondrug Strategies in the Treatment of Musculoskeletal Injury and Disease.
28: Epidemiology of Osteoporosis.
29: Epidemiologic Methods in Studies of Osteoporosis.
30: Genetic Determinants of Osteoporosis.
31: Race, Ethnicity, and Osteoporosis.
32: Geographic Variability in Hip and Vertebral Fractures.
33: Nutrition and Risk for Osteoporosis.
34: Physical Activity and Exercise in the Maintenance of the Adult Skeleton and the Prevention of Osteoporotic Fractures.
35: Premenopausal Reproductive and Hormonal Characteristics and the Risk for Osteoporosis.
36: Clinical and Epidemiological Studies: Skeletal Changes across Menopause.
37: Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization.
38: Falls as Risk Factors for Fracture.
39: Nonskeletal Risk Factors for Osteoporosis and Fractures.
40: Outcomes Following Osteoporotic Fractures.
41: General Pathophysiology of Osteoporosis.
42: Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteoporosis.
43: On the Evolution and Contemporary Roles of Bone Remodeling.
44: Cytokines and the Pathogenesis of Osteoporosis.
45: Animal Models for Osteoporosis.
46: Bone and Fat.
47: Bone Mineral Acquisition in Utero and During Infancy and Childhood.
48: Bone Acquisition in Adolescence.
Color Plates.
Half Title Page.
Title Page.
1: General Pathophysiology of Osteoporosis.
2: Osteoporosis in Childhood and Adolescence.
3: Osteoporosis Associated with Pregnancy.
4: Osteoporosis in Premenopausal Women.
5: Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss.
6: Spectrum of Secondary Osteoporosis.
7: Immobilization Osteoporosis.
8: Osteoporosis Associated with Illnesses and Medications.
9: Glucocorticoid-Induced Osteoporosis.
10: Anticonvulsant-Related Bone Disease.
11: Thyroid Hormone and the Skeleton.
12: The Skeletal Actions of Parathyroid Hormone in Primary Hyperparathyroidism and in Osteoporosis.
13: Osteogenesis Imperfecta and Other Defects of Bone Development as Occasional Causes of Adult Osteoporosis.
14: HIV and Osteoporosis.
15: Obesity, Diabetes, and Fractures.
16: Osteoporosis in Organ Transplant Patients.
17: Osteoporosis Associated with Rheumatologic Disorders.
18: Osteoporosis Associated with Chronic Kidney Disease.
19: Oral Bone Loss and Systemic Osteoporosis: Weighing the Risk Benefit Ratio of Treatment.
20: Cancer and Osteoporosis.
21: Cancer Treatment-Induced Bone Loss in Patients with Breast Cancer: Pathophysiology and Clinical Perspectives.
22: Pathophysiology—Prostate Cancer.
23: Mechanisms of Bone Destruction in Myeloma.
24: Diagnosis and Evaluation.
25: Evaluation of the Patient at Risk for Osteoporosis.
26: Imaging of Osteoporosis.
27: Osteoporosis: Who Should be Treated? Who Should be Screened?.
28: Clinical Use of Bone Densitometry.
29: Biochemical Markers of Bone Turnover in Osteoporosis.
30: Fracture Risk Assessment: The Development and Application of FRAX®.
31: Patient Management.
32: Orthopedic Aspects of Osteoporosis.
33: Falls Prevention Interventions.
34: Physical Therapy, Physical Modalities, and Exercise Regimens in the Management of Osteoporosis.
35: Calcium in the Treatment of Osteoporosis.
36: Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis.
37: Alternative Therapy through Nutrients and Nutraceuticals.
38: Pharmacotherapeutics.
39: Design Considerations for Clinical Investigations of Osteoporosis.
40: Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs.
41: Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis.
42: Androgens.
43: Calcitonin in Osteoporosis.
44: Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis.
45: Osteonecrosis of the Jaw and Atypical Femoral Fractures.
46: Condition Critical: Compliance and Persistence with Osteoporosis Medications.
47: Denosumab for the Treatment of Osteoporosis.
48: Strontium Ranelate in the Prevention of Osteoporotic Fractures.
49: Parathyroid Hormone Treatment for Osteoporosis.
50: New Approaches to Osteoporosis Therapeutics.
51: The Past, Present, and Uncertain Future of Therapeutic Innovation in Osteoporosis.
Color Plates.